SWOG clinical trial number
SWOG-8952 (INT-0111) (CALGB-8952) (EST-5489)

Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs. MOPP/ABV Hybrid

Closed
Phase
Published
Abbreviated Title
Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs. MOPP/ABV Hybrid
Activated
03/01/1990
Closed
11/10/1995

Research committees

Lymphoma

Publication Information Expand/Collapse

2003

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial

DB Duggan;GR Petroni;JL Johnson;JH Glick;RI Fisher;JM Connors;GP Canellos;BA Peterson Journal of Clinical Oncology 21(4):607-614

1997

MOPP/ABV versus ABVD for advanced Hodgkin's disease - a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC).

D Duggan;G Petroni;J Johnson;K Hanson;J Glick;JM Connors;R Chemy;M Barcos;BA Peterson Proc of the American Society of Clinical Oncology 16:12a(#43)

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase